Sublingual Immunotherapy: A Novel, Albeit Not so New, Immunotherapy Treatment Modality

Saporta, Diego

doi:10.2500/ajr.2008.22.3131

Cited by 6 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of sublingual immunotherapy (SLIT) has increased in Europe over the past 20 years 1. However, in the United States, subcutaneous immunotherapy (SCIT) has been the traditional form of immunotherapy for inhalant allergies, and it is currently the only immunotherapy method approved by the U.S. Food and Drug Administration 2.…”

Section: Introductionmentioning

confidence: 99%

Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites

Kim

Mun

Han

et al. 2015

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

PurposeThis study investigated the long-term efficacy, safety, and compliance associated with sublingual immunotherapy (SLIT) in Korean patients with allergic rhinitis sensitized to house dust mites.MethodsThis is a retrospective cohort study. A total of 164 patients who were sensitized to Dermatophagoides pteronyssinus and Dermatophagoides farinae and who received SLIT were enrolled between November 2007 and January 2010. Each patient was followed up using a diary card, on which a symptom score, rescue medication score, and adverse events (AEs) were recorded.ResultsAll allergic rhinitis symptoms improved after 3 years of SLIT (P<0.05), and the rescue medication score decreased with time (P<0.05). The incidence of AEs associated with SLIT was 31% (51 of 164 patients) during the first month of therapy, and there were no severe AEs. The dropout rate was 19.5% (32 of 164 patients) during the first month, 34% (56 of 164 patients) after 6 months, and 41% (68 of 164 patients) after 1 year of SLIT. The 3-year compliance rate was approximately 40% (65 of 164 patients). The most common causes of dropout during the first month of SLIT were high cost and inconvenience. The improvement in allergic symptoms was the most common cause of dropout after 6 months.ConclusionsAllergic symptoms significantly decreased after 1 year of SLIT treatment, and this effect was sustained after 2 or 3 years of treatment. By increasing compliance through patient education, the 3-year use of SLIT for house dust mite allergies may be effective in the management of allergic rhinitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites

Kim

Mun

Han

et al. 2015

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…SLIT is also a very old treatment modality (earliest description is from 1900) and yet, while commonly used in Europe, it is still not well established in the USA [13]. Over the last 20 years the European medical community produced a large amount of high-quality evidence suggesting that SLIT is safer than SCIT [14, 15].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Sublingual Immunotherapy versus Subcutaneous Injection Immunotherapy in Allergic Patients

Saporta

2012

Journal of Environmental and Public Health

Self Cite

View full text Add to dashboard Cite

While it is generally accepted that Subcutaneous Injection Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT) are both efficacious, there is not yet a significant amount of information regarding their comparative efficacy. In this paper, we performed a retrospective chart review and compared treatment results in two groups of patients (both with nasal allergies with or without asthma) that were treated either with SCIT or SLIT. Both treatment modalities were found to be of similar efficacy.

show abstract

“…3 Sublingual immunotherapy (SLIT) has been used in the United States for Ͼ100 years and is being used in Europe with increased frequency for the last 20 years. 4 This treatment has been gradually accepted as a viable alternative to SCIT. According to the World Health Organization Allergic Rhinitis and Its Impact on Asthma guidelines, SLIT could be effective for pollen or mite AR.…”

mentioning

confidence: 99%

Clinical and Immunologic Effects of Sublingual Immunotherapy on Patients with Allergic Rhinitis to House-Dust Mites: 1-Year follow-up Results

Kim

Han

Moon

et al. 2010

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

Sublingual Immunotherapy: A Novel, Albeit Not so New, Immunotherapy Treatment Modality

Abstract: SLIT is a safe treatment modality that should be considered as a useful additional tool in the therapeutic armamentarium.

Cited by 6 publications

References 50 publications

Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites

Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites

Efficacy of Sublingual Immunotherapy versus Subcutaneous Injection Immunotherapy in Allergic Patients

Clinical and Immunologic Effects of Sublingual Immunotherapy on Patients with Allergic Rhinitis to House-Dust Mites: 1-Year follow-up Results

Contact Info

Product

Resources

About